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Abstract
Study Design: Retrospective cohort review
Objectives: Cervical pseudarthrosis is a frequent cause of need for revision anterior cervical discectomy and fusion (ACDF) and
may lead to worse patient-reported outcomes. The effect of proton pump inhibitors on cervical fusion rates are unknown. The
purpose of this study was to determine if patients taking PPIs have higher rates of nonunion after ACDF.
Methods: A retrospective cohort review was performed to compare patients who were taking PPIs preoperatively with those
not taking PPIs prior to ACDF. Patients younger than 18 years of age, those with less than 1-year follow-up, and those undergoing
surgery for trauma, tumor, infection, or revision were excluded. The rates of clinically diagnosed pseudarthrosis and radiographic
pseudarthrosis were compared between PPI groups. Patient outcomes, pseudarthrosis rates, and revision rates were compared
between PPI groups using either multiple linear or logistic regression analysis, controlling for demographic and operative variables.
Results: Out of 264 patients, 58 patients were in the PPI group and 206 were in the non-PPI group. A total of 23 (8.71%) patients were
clinically diagnosed with pseudarthrosis with a significant difference between PPI and non-PPI groups (P ¼ .009). Using multiple linear
regression, PPI use was not found to significantly affect any patient-reported outcome measure. However, based on logistic regression,
PPI use was found to increase the odds of clinically diagnosed pseudarthrosis (odds ratio 3.552, P¼ .014).Additionally, clinically diagnosed
pseudarthrosis negatively influenced improvement in PCS-12 scores (P ¼ .022).
Conclusions: PPI use was found to be a significant predictor of clinically diagnosed pseudarthrosis following ACDF surgery.
Furthermore, clinically diagnosed pseudarthrosis negatively influenced improvement in PCS-12 scores.
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Introduction
Anterior cervical discectomy and fusion (ACDF) has been
established as a reliable treatment for cervical spine radiculo-
pathy and myelopathy. In the United States, there are approx-
imately 70 cervical spine surgeries performed annually for
every 100 000 people, and ACDF procedures account for
68% of all cervical surgeries.1 Despite its reliability, known
complications following ACDF include pseudarthrosis, graft
subsidence, and adjacent segment disease.2 Pseudarthrosis is
the leading cause of revision ACDF procedures, accounting for
an estimated 45% and 56% of all revision procedures.3 The risk
of pseudarthrosis has been estimated to be as high as 20% of
patients with a single-level fusion and as high as 60% in
patients with a multilevel fusion.2 Pseudarthrosis can result
in abnormal segmental motion that can lead to persistent neck
pain and radicular symptoms as well as increase the risk of
hardware failure.2
Known patient risk factors that increase the risk of pseudar-
throsis include smoking, diabetes, obesity, age, osteoporosis,
and poor nutritional status.4-6 Proton pump inhibitors (PPIs) are
a widely prescribed class of medications used to treat gastro-
esophageal reflux disease (GERD), whose side effects include
malnutrition, alterations in the immune system’s effectiveness,
as well as changes in bone metabolism.7,8 PPIs were the third
most commonly prescribed medication in the United States in
2008 and first-generation PPIs have been available over-the-
counter since 2003; thus, many patients may be using the drug
without self-reporting use.9,10 Basic science studies have
demonstrated that PPIs alter bone healing and metabolism
through decreasing the effectiveness of bone resorption by
osteoclasts.7 Despite their widespread use and their effects on
the musculoskeletal system, there has been relatively little pub-
lished regarding the effects of PPIs in orthopedic surgery and
specifically spinal fusion. The purpose of this study was to
determine if there was an association between PPI use and the
development of a pseudarthrosis after ACDF.
Methods
After institutional review board approval was obtained, a ret-
rospective cohort review was performed via analysis of
patient records obtained from a single institution’s electronic
medical record (EMR) system. All the patients included
underwent ACDF performed by one of several fellowship-
trained orthopedic spine surgeons between January 1, 2015,
and December 31, 2016. Patients over the age of 18 who
underwent surgery to address radiculopathy, myelopathy, or
myeloradiculopathy symptoms were included. Patients were
grouped based on their documented preoperative use of PPIs
in the EMR. Patients under the age of 18 years, those with less
than a year of follow-up, or patients that received surgery for
trauma, infection, metastatic disease, or revision were
excluded from this study.
Basic demographic data for the patients in the cohort includ-
ing age, sex, body mass index (BMI), months followed-up,
preoperative symptom duration, smoking status, number of
levels fused, graft type utilized, preoperative cervical diagno-
sis, and presence of adjacent level spondylolisthesis was col-
lected and recorded. Patient-reported outcome measurements
(PROMs) from at least 1-year follow-up, including the Neck
Disability Index (NDI), Short Form-12 Physical Component
Score (PCS-12), Short Form-12 Mental Component Score
(MCS-12), and both Visual Analogue Scale Neck (VAS Neck)
and Arm (VAS Arm) pain scores were collected and compared
between the PPI groups.
The primary endpoint of this study was the rate of clinical
diagnosis of pseudarthrosis based on persistent neck pain or
radicular symptoms at follow-up. Based on surgeon prefer-
ence, all patients with clinically diagnosed pseudarthrosis
subsequently had radiographic confirmation using either a
computed tomography (CT) scan, static anteroposterior
(AP) and lateral cervical radiographs, or dynamic lateral flex-
ion and extension radiographs. However, since this institution
does not routinely obtain CT scans at follow-up and only a
small subset of patients underwent CT, the rate of radio-
graphic pseudarthrosis on dynamic radiographs was chosen
as a secondary endpoint. Some patients received dynamic
radiographs at routine follow-up due to surgeon-specific post-
operative protocol, even if they had no cervical symptoms.
The criteria used for determining radiographic pseudarthrosis
on flexion and extension radiographs was previously defined
by Song et al, where an interspinous motion of 1 mm between
flexion and extension films at the surgically fused levels com-
bined with 4 mm of interspinous motion at the superjacent
unfused levels.11 All images were obtained from the institu-
tion’s Picture Archiving and Communication System (PACS;
Siemens Magic Software, Munich Germany; precision of
0.1 mm). Both PPI groups were also compared for differences
in cervical revision surgery rates.
Statistical Analysis
Standard descriptive statistics including mean and 95% con-
fidence interval were used for univariate analysis of basic
demographic data and patient reported outcomes. The
recovery ratio (RR) was calculated using the following
equation: (D outcome score)/(optimal score  baseline
score). The optimal scores for NDI, VAS Neck, and VAS
Arm pain were defined as 0, while the those for PCS-12 and
MCS-12 were defined as 100.12 The percentage of patients
reaching a minimal clinically important difference (MCID)
after surgery was calculated and compared between groups
using Pearson w2 analysis. The following MCID cutoff
scores were used: NDI, 15 points; PCS-12, 8.1 points;
MCS-12, 4.7 points; VAS Neck, 2.5 points; and VAS Arm,
2.5 points.13,14 Multiple linear regression analysis was used
to determine if PPI use was a significant predictor of patient
outcomes, controlling for demographic and operative vari-
ables. Multiple logistic regression was used to determine if
PPI use increased odds of nonunion rates or cervical revi-
sion rates. Continuous variables were compared using
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independent t tests or Mann-Whitney U test, depending on
normality of the data. Categorical variables were compared
using Fisher’s exact or Pearson’s w2 test. A P value <.05
was considered statistically significant.
Results
Demographic Data
A total of 264 patients were included in our analysis based on
inclusion criteria. Overall, there were a total of 206 patients
who were not taking a PPI versus 58 patients that were taking a
PPI prior to surgery. There were no baseline differences in
demographics except for sex, with the PPI group having a
higher proportion of females (64.6% vs 50%, P ¼ .036). The
average age for all patients was 53 years, and the mean BMI
was 29.6. The mean follow-up was 19.8 months. With regard to
duration of symptoms preoperatively, 18 (6.8%) experienced
less than 1 month of symptoms, 41 (15.5%) experienced 1 to
3 months, 46 (17.4%) experienced 3 to 6 months, 72 (27.3%)
experienced 6 months to 2 years, and 87 (33.0%) experienced
2þ years (P ¼ .434). Descriptive statistics for the entire cohort
can be found in Table 1.
Patient-Reported Outcome Measurements
Overall, there were no significant differences in outcome
scores, recovery ratios, or % of patients reaching MCID in
terms (Table 2). Based on multiple linear regression analysis,
PPI use was not found to be a significant predictor for change in
any outcome score: NDI (P¼ .578), PCS-12 (P¼ .841), MCS-
12 (P¼ .909), VAS Neck (P¼ .654), and VAS Arm (P¼ .762;
Table 2). Additional regression analysis revealed that a higher
BMI was found to negatively influence NDI score (b ¼ 0.498
[0.103, 0.893], P¼ .014). Length of follow-up was also found to
be a significant predictor of changes in NDI (b ¼ 0.521 [0.142,
0.900], P ¼ .007) and VAS Neck (b ¼ 0.081 [0.019, 0.142],
P ¼ .010). Longer duration of preoperative symptoms was
found to negatively affect NDI (b ¼ 2.373 [0.503, 4.243],
P ¼ .013) and MCS-12 (b ¼ 1.795 [3.137, 0.453],
P ¼ .009) scores. In addition, the preoperative diagnosis was
a significant predictor of MCS-12 score (b ¼ 2.294 [0.207,
4.380], P ¼ .031), with the presence of myelopathy and mye-
loradiculopathy predicting improved outcomes. Smoking
status was a significant predictor of VAS Neck scores
(b ¼ 0.497 [0.949, 0.045], P ¼ .031) and iliac crest
bone graft use influenced VAS Arm scores (b ¼ 2.579
[0.806, 4.352], P ¼ .005).
Table 1. Descriptive Characteristics of the Cohort by PPI Use.
Overall (N ¼ 264) On PPI (N ¼ 58) Not on PPI (N ¼ 206) P
Age, mean [95% CI] 53 [52, 54] 55 [52, 58] 53 [51, 54] P ¼ .974
Sex, n (%) P ¼ .036*
Male 123 (47%) 20 (34.5%) 103 (50%)
Female 141 (53%) 38 (64.6%) 103 (50%)
BMI, mean [95% CI] 29.6 [28.8, 30.3] 30.5 [28.9, 32.0] 29.3 [28.5, 30.1] P ¼ .697
Months follow-up, mean [95% CI] 19.8 [19.0, 20.6] 19.1 [17.4, 20.8] 20.0 [19.1, 20.9] P ¼ .784
Symptom duration, n (%) P ¼ .434
<1 Month 18 (6.8%) 3 (5.2%) 15 (7.3%)
1-3 Months 41 (15.5%) 9 (15.5%) 32 (15.5%)
3-6 Months 46 (17.4%) 13 (22.4%) 33 (16.0%)
6 Months to 2 years 72 (27.3%) 11 (19.0%) 61 (29.6%)
2 Yearsþ 87 (33.0%) 22 (37.9%) 65 (31.6%)
Smoking status, n (%) P ¼ .126
Never 152 (57.6%) 30 (51.7%) 122 (59.2%)
Current 43 (16.3%) 7 (12.1%) 36 (17.5%)
Former 69 (26.1%) 21 (36.2%) 48 (23.3%)
# Levels fused, n (%) P ¼ .158
1 61 (23%) 12 (20.7%) 49 (23.8%)
2 125 (47%) 27 (46.6%) 98 (47.6%)
3 65 (25%) 13 (22.4%) 52 (25.2%)
4 12 (5%) 5 (8.6%) 7 (3.4%)
5 1 (<1%) 1 (1.7%) 0 (0%)
Graft type, n (%) P ¼ .493
Allograft 243 (92.0%) 54 (93.1%) 189 (83.6%)
Iliac crest bone graft 21 (8.0%) 4 (6.9%) 17 (16.4%)
Diagnosis, n (%) P ¼ .357
Radiculopathy 122 (46.2%) 22 (37.9%) 100 (48.5%)
Myelopathy 64 (24.2%) 16 (27.6%) 48 (23.3%)
Myeloradiculopathy 78 (29.6%) 20 (44.5%) 58 (28.2%)
Abbreviations: PPI, proton pump inhibitor; CI, confidence interval; BMI, body mass index.
*Indicates statistical significance (P < .05).
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Pseudarthrosis and Cervical Revision Rates
Twenty-three patients (8.71%) were clinically diagnosed with
symptomatic pseudarthrosis out of the entire cohort of
264 patients (Table 3). There was a significant difference
between groups, with 10 patients in the PPI group (17.2% of
all patients taking a PPI) and the remaining 13 (6.3% of all
patients not taking a PPI) in the non-PPI (P ¼ .009). Philips
iSite (Philips Health, USA) was used which has a measurement
error rate of +0.5 mm per measurement. Of the 264 patients,
150 had dynamic radiographs performed at follow-up, all
patients had AP and lateral radiographs taken. Using the pre-
viously mentioned dynamic radiographic criteria for pseudar-
throsis developed by Song et al, 21 of 150 (14.0%) patients
were found to have pseudarthrosis (Table 3) with 7 (33.3%) in
the PPI group and the other 14 (66.7%) in the non-PPI group
(P ¼ .100). There were a total of 22 patients that underwent
cervical revision surgery to address pseudarthrosis, with 5
(22.7%) patients belonging to the PPI group and 17 (77.3%)
belonging to the non-PPI group (P ¼ .929; Table 4).
Using multiple logistic regression, PPI use was found to
increase odds of clinically diagnosed pseudarthrosis by 3.5 fold
(b ¼ 1.268, odds ratio [OR] ¼ 3.552, P ¼ .014), but not for
rates of pseudarthrosis on dynamic radiographs (P ¼ .381) or
rates of cervical revision surgery (P ¼ .685). In addition,
patients with a 3 or more level fusion had a 13-fold and
10-fold increased odds of radiographic pseudarthrosis
compared to a 1-level and 2-level fusion, respectively ([b ¼
2.564, OR ¼ 13.0, P ¼ .044] for 1-level; [b ¼ 2.313, OR ¼
10.1, P ¼ .027] for 2-level). None of the other factors included
in logistic regression were found to be significant predictors of
cervical revision surgery or pseudarthrosis.
When comparing outcome scores in patients with a clini-
cally diagnosed pseudarthrosis, postoperative VAS Neck and
Arm scores were found to be significantly different (P ¼ .002
and P ¼ .001, respectively; Table 5) with the pseudarthrosis
group exhibiting worse disability in each of these domains. In
addition, these patients exhibited diminished recovery in PCS-
12 (P ¼ .035) and VAS Neck scores (P ¼ .035). On linear
regression analysis, clinically diagnosed pseudarthrosis nega-
tively influenced improvement in PCS-12 (b ¼ 4.865
[9.025, 0.706], P ¼ .022). When comparing outcomes
between patients with pseudarthrosis diagnosed on dynamic
radiographs, patients with pseudarthrosis showed diminished
recovery in PCS-12 scores (P ¼ .019; Table 6), but none of
the other PROMs.
Discussion
ACDF is a common and reliable surgery for the treatment of
cervical radiculopathy and myelopathy. However, pseudarthro-
sis is a well-known complication following ACDF and is one of
the leading causes for revision surgery.3 While there are several
well-established risk factors for cervical pseudarthrosis includ-
ing age, diabetes, obesity, smoking, osteoporosis, and malnu-
trition, there are no studies assessing the preoperative use of
PPIs as a risk factor. Currently, PPIs are the leading class of
medications prescribed for the treatment of GERD.15 Recent
studies have shown that many PPIs are inappropriately pre-
scribed, raising questions regarding safety with long-term
use.15 In addition, many patients may be taking PPIs without
reporting its use since they are readily available over-the-
counter. PPIs achieve their effect by decreasing the production
of stomach acid; however, they are known to affect osteo-
clasts and thus influence bone metabolism and delay spinal
fusion rates in animal studies.7,8 Some studies have found a
modest association with PPI use and spine fractures, but no
studies thus far have assessed the effect of preoperative PPI
use on patient outcomes or pseudarthrosis following cervical
spine surgery.16,17
The results of this study demonstrate that patients with
preoperative PPI use had a higher rate of clinically
Table 2. Preoperative and Postoperative Patient-Reported Outcome
Measurements Comparisons Between PPI Groupsa.
On PPI (N ¼ 58) Not on PPI (N¼ 206) Pb Pc
NDI .578
Pre 42.9 [37.9, 47.9] 42.3 [39.6, 45.0] .766
Post 24.1 [18.7, 29.6] 26.0 [22.9, 29.2] .103
D 18.9 [24.2,13.5] 16.2 [19.0,13.5] .373
RR 0.32 [0.12, 0.52] 0.38 [0.31, 0.44] .507 —
% MCID 58.6% 46.1% .092 —
PCS-12 .841
Pre 32.5 [30.5, 34.5] 33.4 [32.3, 34.5] .524
Post 39.6 [36.8, 42.5] 40.8 [39.3, 42.3] .514
D 7.2 [5.0, 9.9] 7.2 [5.9, 8.5] .994
RR 0.10 [0.06, 0.14] 0.10 [0.08, 0.12] .918 —
% MCID 43.1% 45.1% .782 —
MCS-12 .909
Pre 44.3 [41.3, 47.3] 45.6 [43.9, 47.3] .359
Post 48.2 [45.2, 51.2] 49.4 [47.8, 51.0] .688
D 3.8 [0.1, 7.6] 3.6 [1.7, 5.6] .934
RR 0.04 [0.03, 0.11] 0.03 [0.00, 0.07] .933 —
% MCID 48.3% 42.7% .451 —
VAS Neck .654
Pre 5.7 [4.8, 6.5] 5.7 [5.3, 6.1] .618
Post 3.2 [2.4, 4.0] 3.1 [2.7, 3.5] .810
D 2.5 [3.4, 1.6] 2.5 [2.9, 2.1] .991
RR 0.46 [0.33, 0.60] 0.41 [0.32, 0.50] .583 —
% MCID 50.0% 44.2% .431 —
VAS Arm .762
Pre 5.7 [4.9, 6.5] 5.0 [4.5, 5.4] .112
Post 3.1 [2.3, 3.8] 2.7 [2.3, 3.1] .269
D 2.7 [3.6, 1.8] 2.3 [2.8, 1.8] .512
RR 0.47 [0.33, 0.62] 0.51 [0.41, 0.61] .705 —
% MCID 50.0% 44.7% .471 —
Abbreviations: PPI, proton pump inhibitor; RR, recovery ratio; MCID, minimal
clinically important difference; NDI, Neck Disability Index; SF-12, Short Form-
12; PCS-12, Physical Component Score of SF-12; MCS-12, Mental Component
Score of SF-12; VAS, Visual Analogue Score; VAS Neck, VAS neck pain; VAS
Arm, VAS arm pain.
aValues are reported as mean [95% CI].
bIndependent samples t tests (preoperative, postoperative, and D scores, and
recovery ratios, between groups), or Pearson w2 analysis (% MCID).
cMultiple linear regression analysis.
58 Global Spine Journal 10(1)
diagnosed pseudarthrosis compared with patients that were
not taking preoperative PPIs (P ¼ .009). Additionally, pre-
operative PPI use was demonstrated to be an independent
risk factor of a pseudarthrosis on logistic regression analysis
(OR ¼ 3.552, P ¼ .014). However, PPIs were not associated
with a significantly higher revision rate in this cohort and
PPI use did not influence patient reported outcomes after
ACDF at the 1-year time point.
PPIs are a common class of medication that is seen fre-
quently in patients presenting to the orthopedic and spine
clinic. They are the mainstay of treatment for GERD, which
has been estimated to affect 20% of the US population.18 Addi-
tionally, PPIs are the standard of care for stress ulcer prophy-
laxis in hospitalized and critical care patients.19 They exert
their effect by blocking hydrogen-potassium ATPase pumps
to decrease acid production of gastric parietal cells. However,
this blockade is not specific for the gastric mucosa and affects
similar ion pumps of osteoclasts, macrophages, and other
immune system cell types.20 These alterations in osteoclast
function in turn affect bone metabolism by decreasing trabe-
cular bone density and may also affect bone healing, potentiat-
ing the risk of fractures.8 Histing et al found that administration
of daily PPIs in a mouse femur fracture model resulted in
significantly degraded biomechanics with higher amounts of
cartilaginous and fibrous tissue and deceased bone formation.7
In addition, these mice also showed reduced amounts of the
bone formation markers bone morphogenic protein (BMP)-2,
BMP-4, and cysteine-rich protein (CYR61).7 Currently, the
biology of endochondral bone formation in fracture healing is
well understood, and while the biology of spinal fusion may not
be fully delineated, it shares significant similarities.21 The full
interactions of PPIs with critical steps involved in spinal fusion
are currently not known.
Population-wide studies have also been done evaluating
fracture risk and PPI use. Vestergaard et al, in a case-
control study of the Danish population, demonstrated that
PPI use resulted in an increased risk of hip, wrist, and spine
fractures.22 This has been acknowledged by Federal Drug
Administration, which has labeled PPIs as being known to
increase the likelihood of a fracture.10 There is also growing
evidence of an association between prolonged PPI use and
increased risk of spine fractures.16,17 This growing body of
evidence relating PPIs and fractures suggest that these med-
ications have an adverse effect on bone quality and may
affect stability with instrumentation in elective spine fusion.
The present study did not assess the incidence of fractures
or hardware complications postoperatively, but it did find a
significantly higher clinical pseudarthrosis rate (OR ¼
3.552, P ¼ .014) in patients taking PPI, suggesting a sig-
nificant interaction. The effects of PPI use on fusion rates
after elective spine surgery are not fully understood and
deserve further attention.
Pseudarthrosis after ACDF is a relatively common post-
operative complication and is clinically apparent when patients
present with recurrent or worsening radicular symptoms or
neck pain.2,23 However, patients with pseudarthrosis do not
Table 3. Pseudarthrosis Rates and PPI Usea.
Overall On PPI Not on PPI Pb Pc
Clinical diagnosis of pseudarthrosis (N ¼ 264) (N ¼ 58) (N ¼ 206)
Yes, n (%) 23 (8.7%) 10 (17.2%) 13 (6.3%) .009* .014*
No, n (%) 241 (91.3%) 48 (82.8%) 193 (93.7%)
Pseudarthrosis on dynamic radiographs (N ¼ 150) (N ¼ 30) (N ¼ 120)
Yes, n (%) 21 (14.0%) 7 (23.3%) 14 (11.7%) .100 .381
No, n (%) 129 (86.0%) 23 (76.7%) 106 (88.3%)
Abbreviation: PPI, proton pump inhibitor.
a Revision surgery, and clinical and radiographic pseudarthrosis, between PPI groups.
bPearson w2 analysis or Fisher’s exact test.
bBinary logistic regression.
*Indicates statistical significance (P < .05).
Table 4. Revision Rates and PPI Usea.
Overall (N ¼ 264) On PPI (N ¼ 58) Not on PPI (N ¼ 206) Pb Pc
Total, n (%) 22 (8.3%) 5 (8.6%) 17 (8.3%) .929 .685
Pseudarthrosis 15 2 (3.5%) 13 (6.3%) .531 .413
Adjacent segment disease 7 3 (5.2%) 2 (91.7%)
New onset myelopathy 1 — 1 (0.5%)
Seroma 1 — 1 (0.5%)
Abbreviation: PPI, proton pump inhibitor.
aReasons for revision between PPI groups.
bPearson w2 analysis or Fisher’s exact test.
cBinary logistic regression.
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always present with symptoms and the management of asymp-
tomatic pseudarthrosis remains controversial.2 Lee et al
recently evaluated the results of patients that had a pseudar-
throsis after ACDF at 1 year after surgery. In their study, they
identified 32.6% (29/89) of patients had a pseudarthrosis at
1-year point, and out of these 29 patients, 21 went on to achieve
bony union by the 2-year point.2 Persistent nonunion in their
cohort was associated with worse functional outcomes at
2 years in terms of VAS Neck and NDI scores; however, it is
unclear whether these patients had radiographic or clinically
diagnosed pseudarthrosis.2 Delamarter et al, on the other
hand, evaluated the reoperation rates of patients undergoing
ACDF and identified that 13.1% (8/61) underwent a revision
procedure at their index surgical level and 75% (6/8)
of those patients underwent revision for a symptomatic pseu-
darthrosis.20 Similarly, Kaiser et al suggest that revision of a
symptomatic pseudarthrosis should be considered as this is
associated with an improved clinical outcome.23 Despite a dif-
ference in clinical pseudarthrosis rates, this study did not find a
significant difference in reoperation rates (P ¼ .929) between
groups and PPI use was not a significant predictor of revision
(P¼ .685) on regression analysis. In addition, while the present
study did not identify any significant differences in PROMs
postoperatively between PPI groups, patients with clinical
pseudarthrosis reported worse postoperative VAS Neck and
VAS Arm scores (P ¼ .002 and P ¼ .001) and the presence
Table 5. Preoperative and Postoperative Patient-Reported Outcome
Measurements Comparisons Between Pseudarthrosis Groupsa.




(N ¼ 23) Pb Pc
NDI
Pre 41.9 [39.4, 44.3] 48.3 [39.0, 57.6] .766 .407
Post 24.7 [21.9, 27.5] 35.1 [24.3, 45.9] .103
D 17.2 [19.6,14.6] 13.0 [21.9,4.1] .317
RR 0.39 [0.33, 0.45] 0.11 [0.32, 0.54] .184 —
% MCID 49.4% 43.5% .589 —
PCS-12
Pre 33.5 [32.4, 34.5] 30.2 [27.3, 33.1] .454 .022*
Post 41.2 [39.8, 42.6] 33.2 [29.1, 37.3] .288
D 7.6 [6.4, 8.8] 3.0 [1.5, 7.5] .067
RR 0.11 [0.09, 0.13] 0.04 [0.03, 0.10] .035* —
% MCID 45.6% 34.8% .317 —
MCS-12
Pre 45.3 [43.8, 46.9] 45.3 [39.7, 50.8] .419 .661
Post 49.2 [47.7, 50.7] 48.5 [43.6, 53.4] .288
D 3.7 [2.0, 5.5] 3.0 [4.4, 10.4] .842
RR 0.04 [0.01, 0.07] 0.01 [0.12, 0.14] .818 —
% MCID 43.6% 47.8% .694 —
VAS Neck
Pre 5.6 [5.3, 6.0] 6.2 [4.8, 7.6] .999 .113
Post 3.0 [2.6, 3.4] 4.7 [3.4, 6.1] .002*
D 2.6 [3.0, 2.2] 1.5 [2.8, 0.2] .096
RR 0.44 [0.36, 0.52] 0.26 [0.06, 0.45] .035* —
% MCID 46.9% 30.4% .130 —
VAS Arm
Pre 5.0 [4.6, 5.4] 6.5 [5.4, 7.7] .815 .997
Post 2.7 [2.3, 3.0] 3.8 [2.5, 5.2] .001*
D 2.3 [2.8, 1.9] 2.8 [4.0, 1.5] .769
RR 0.51 [0.42, 0.60] 0.43 [0.25, 0.62] .174 —
% MCID 46.1% 43.5% .812 —
Abbreviations: NDI, Neck Disability Index; RR, recovery ratio; MCID, minimal
clinically important difference; SF-12, Short Form-12; PCS-12, Physical Com-
ponent Score of SF-12; MCS-12, Mental Component Score of SF-12; VAS,
Visual Analogue Score; VAS Neck, VAS neck pain; VAS Arm, VAS arm pain.
aPreoperative and postoperative values are reported as mean [95% CI].
bMann-Whitney U test (preoperative, postoperative, and D scores, and recov-
ery ratios, between groups), or Pearson w2 analysis (% MCID).
cMultiple linear regression analysis.
*Indicates statistical significance (P < .05).
Table 6. Preoperative and Postoperative Patient-Reported Outcome
Measurements Comparisons Between Radiographic Pseudarthrosis
Groupsa.




(N ¼ 21) Pb Pc
NDI
Pre 42.7 [39.6, 45.8] 44.6 [35.4, 53.8] .355 .935
Post 25.2 [21.5, 29.0] 27.6 [17.1, 38.1] .762
D 17.3 [20.8,13.9] 18.1 [26.8,9.5] .717
RR 0.39 [0.31, 0.47] 0.34 [0.15, 0.54] .535 —
% MCID 51.9% 47.6% .713 —
PCS-12
Pre 32.7 [31.4, 33.9] 30.8 [26.9, 34.7] .462 .064
Post 41.8 [39.8, 43.7] 35.3 [30.2, 40.4] .211
D 8.9 [7.2, 10.6] 4.2 [2.2, 10.5] .146
RR 0.13 [0.10, 0.15] 0.04 [0.03, 0.12] .019* —
% MCID 49.6% 33.3% .166 —
MCS-12
Pre 45.9 [43.8, 48.0] 47.9 [43.3, 52.5] .439 .541
Post 49.4 [47.4, 51.4] 49.2 [43.8, 54.6] .211
D 3.3 [0.9, 5.7] 0.3 [6.2, 6.8] .505
RR 0.03 [0.01, 0.07] 0.01 [0.11, 0.09] .521 —
% MCID 40.3% 33.3% .544 —
VAS Neck
Pre 5.7 [5.2, 6.2] 6.2 [4.9, 7.5] .954 .879
Post 3.2 [2.7, 3.7] 3.8 [2.3, 5.2] .225
D 2.4 [3.0, 1.9] 2.2 [3.4, 1.1] .736
RR 0.46 [0.38, 0.54] 0.33 [0.16, 0.51] .182 —
% MCID 45.7% 33.3% .288 —
VAS Arm
Pre 4.6 [4.0, 5.1] 5.0 [3.5, 6.5] .566 .609
Post 2.6 [2.1, 3.0] 3.4 [1.8, 5.1] .125
D 1.9 [2.6, 1.2] 1.9 [4.1, 0.3] .886
RR 0.54 [0.44, 0.64] 0.40 [0.10, 0.69] .280 —
% MCID 45.0% 33.3% .319 —
Abbreviations: NDI, Neck Disability Index; RR, recovery ratio; MCID, minimal
clinically important difference; SF-12, Short Form-12; PCS-12, Physical Com-
ponent Score of SF-12; MCS-12, Mental Component Score of SF-12; VAS,
Visual Analogue Score; VAS Neck, VAS neck pain; VAS Arm, VAS arm pain.
aPreoperative and postoperative values are reported as mean [95% CI].
bMann-Whitney U test (preoperative, postoperative, and D scores, and recov-
ery ratios, between groups), or Pearson w2 analysis (% MCID).
cMultiple linear regression analysis.
*Indicates statistical significance (P < .05).
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of pseudarthrosis negatively influenced improvement in PCS-
12 scores (P ¼ .022).
This analysis is the first to look at the association between
PPIs and the development of a pseudarthrosis after ACDF. In
this cohort, preoperative PPI use was identified as an inde-
pendent predictor of developing a pseudarthrosis after ACDF
(P ¼ .014). While this study did not identify a difference in
revision rates or pseudarthrosis on dynamic radiographs, the
difference in clinically diagnosed pseudarthrosis is a pertinent
one. Spine surgeons should be aware of patients taking PPIs
preoperatively as this may increase the risk of the develop-
ment of a clinically symptomatic pseudarthrosis after ACDF
necessitating possible revision. In their analysis, Vestergaard
et al identified that patients on histamine (H2) blockers had a
decreased fracture risk compared with patients on PPIs as well
as the rest of the general population. This may represent a
perioperative alternative for patients on PPIs presenting for
elective ACDF.22 The risks and benefits of PPI use in the
perioperative period or the alteration of therapy should be
tailored to each individual patient’s situation. Future studies
to understand the effect of PPIs on patients undergoing spinal
fusion is necessary.
There are several limitations to this retrospective study.
Preoperative PPI use was identified based on patient-
reported medications as well as preoperative medical
clearance forms. Due to the fact that PPIs are available
over-the-counter some patients may have failed to reported
usage of this medication. Also due to the retrospective
nature of this study, we are unable to identify the full
duration of PPI use prior to surgery. Since further investi-
gation for pseudarthrosis after ACDF is generally deter-
mined by the presence of symptoms, our study was
designed to determine the rates of clinical pseudarthrosis
as would be detected in clinical follow-up. We acknowl-
edge that this study design has some limitations, among
which include a decreased ability to determine clinically
silent nonunions. In addition, the mean follow-up was
around 19 months, which may not be long enough to deter-
mine whether a clinically symptomatic pseudarthrosis may
resolve or require further intervention. Similarly, no dif-
ferences in revision rates were found, which may be sig-
nificant at a longer follow-up. Finally, radiographs and not
CT was used to determine pseudarthrosis, which may have
underestimated radiographic nonunion rates.
Conclusion
In conclusion, this is the first study to associate PPI use with a
risk of developing a symptomatic pseudarthrosis after ACDF.
Patients on preoperative PPIs did not have a difference identi-
fied in their pre- and postoperative outcomes measures; how-
ever, patients with pseudarthrosis has significantly worse VAS
Neck and VAS Arm scores. Further investigation into the rela-
tionship of PPIs and the development of pseudarthrosis of the
cervical spine is needed.
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